Clinical trial
A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
NCT00669825 is registered in ClinicalTrials.gov with Alvine Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
- Lead sponsor
- Alvine Pharmaceuticals Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- October 31, 2008
- Enrollment
- 36 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.